Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?

References

• Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of Microsatellite Instability-High solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi: 10.1158/1078-0432.CCR-18-4070
   PubMed Web of Science ®Google Scholar
• Hajdu SI, Vadmal M. A note from history: landmarks in history of cancer, part 6. Cancer. 2013;119(23):4058–4082. doi: 10.1002/cncr.28319
   PubMed Web of Science ®Google Scholar
• Corti C, Antonarelli G, Valenza C, et al. Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe? Eur J Cancer. 2022;171:25–42. doi: 10.1016/j.ejca.2022.04.039
   PubMed Web of Science ®Google Scholar
• Hynes N. The biology of erbB-2/nue/HER-2 and its role in cancer. Biochim Biophys Acta (BBA) - Reviews on Cancer. 1994;1198(2–3):165–184. doi: 10.1016/0304-419X(94)90012-4
   PubMed Web of Science ®Google Scholar
• Gion M, Trapani D, Cortés A, et al. Systemic therapy for HER2-positive metastatic breast cancer: moving into a new era. Am Soc Clin Oncol Educ Book. 2022;(42):82–92. doi: 10.1200/EDBK_351222
   Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–131. doi: 10.1056/NEJMoa1703643
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi: 10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi: 10.1056/NEJMoa1914609
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi: 10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Hegg R, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022;401:105–117. doi: 10.1016/S0140-6736(22)02420-5
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi: 10.1056/NEJMoa1914510
   PubMed Web of Science ®Google Scholar
• André F, Hee Park Y, Kim S-B, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773–1785. doi: 10.1016/S0140-6736(23)00725-0
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–653. doi: 10.1016/S1470-2045(17)30111-0
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang Y-J, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. J Clin Oncol. 2016;34(5):443–451. doi: 10.1200/JCO.2015.62.6598
   PubMed Web of Science ®Google Scholar
• Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–1384. doi: 10.1016/S1470-2045(18)30481-9
   PubMed Web of Science ®Google Scholar
• Blangé D, Stroes CI, Derks S, et al. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: a systematic review. Cancer Treat Rev. 2022;108:102418. doi: 10.1016/j.ctrv.2022.102418
   PubMed Web of Science ®Google Scholar
• Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–2430. doi: 10.1056/NEJMoa2004413
   PubMed Web of Science ®Google Scholar
• Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24(5):496–508. doi: 10.1016/S1470-2045(23)00150-X
   PubMed Web of Science ®Google Scholar
• Strickler JH, Cercek A, Ng K, et al. HER2 testing in the MOUNTAINEER trial: analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS. J Clin Oncol. 2023;41(16_suppl):3528–3528. doi: 10.1200/JCO.2023.41.16_suppl.3528
   Google Scholar
• Yoshino T, Di Bartolomeo M, Raghav K, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023;14(1):3332. doi: 10.1038/s41467-023-38032-4
   PubMed Web of Science ®Google Scholar
• Raghav KPS, Siena S, Takashima A, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. J Clin Oncol. 2023;41(16_suppl):3501–3501. doi: 10.1200/JCO.2023.41.16_suppl.3501
   Web of Science ®Google Scholar
• Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J Clin Oncol. 2023;41(17_suppl):LBA3000–LBA3000. doi: 10.1200/JCO.2023.41.17_suppl.LBA3000
   Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N Engl J Med. 2022;386(3):241–251. doi: 10.1056/NEJMoa2112431
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Eli LD, Wildiers H, et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023;34(10):885–898. doi: 10.1016/j.annonc.2023.08.003
   PubMedGoogle Scholar